Magle Chemoswed Holding's Annual Report for 2023 has been published on the Group’s website as of today.

The annual report is available as a downloadable PDF document at www.maglegroup.com

"In 2023, we successfully delivered solid revenue growth and improved profitability, based on our long-term strategy to create value for shareholders, business partners, and patients all over the globe," said Justin Pierce, Magle Group's CEO.

Petra Jönsson Sjölin, Magle Group's CFO, said, "The financial performance for the year, with total revenue of SEK 183 million and Net profit of SEK12.2 million, shows continued growth and stability which are evidence of our balanced risk-based-approach".

Contacts

Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and https://maglegroup.com/ and www.maglepharmacept.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

Attachments

MCSH Annual Report 2023

© Modular Finance, source Nordic Press Releases